Zacks Research Comments on Glaukos’ Q4 Earnings (NYSE:GKOS)

Glaukos Co. (NYSE:GKOS) – Research analysts at Zacks Research increased their Q4 2026 earnings estimates for shares of Glaukos in a report released on Wednesday, May 21st. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will post earnings per share of $0.11 for the quarter, up from their previous forecast of $0.06. The consensus estimate for Glaukos’ current full-year earnings is ($1.08) per share.

GKOS has been the topic of several other research reports. Piper Sandler decreased their price target on Glaukos from $180.00 to $165.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 15th. Stephens decreased their target price on Glaukos from $140.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, May 2nd. Morgan Stanley lowered their target price on Glaukos from $110.00 to $72.00 and set an “underweight” rating for the company in a research note on Tuesday, May 6th. Truist Financial restated a “buy” rating and issued a $135.00 price target (down from $140.00) on shares of Glaukos in a research note on Thursday, May 1st. Finally, Wells Fargo & Company lowered shares of Glaukos from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $160.00 to $86.00 in a report on Thursday, May 1st. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $134.67.

Glaukos Stock Down 2.6%

Shares of GKOS opened at $94.98 on Thursday. The firm has a 50 day simple moving average of $93.63 and a two-hundred day simple moving average of $125.20. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. Glaukos has a one year low of $77.10 and a one year high of $163.71. The company has a market cap of $5.43 billion, a P/E ratio of -33.09 and a beta of 0.83.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.11. The company had revenue of $106.66 million during the quarter, compared to the consensus estimate of $102.78 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The firm’s quarterly revenue was up 24.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.70) EPS.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Rhumbline Advisers grew its position in shares of Glaukos by 0.3% in the 4th quarter. Rhumbline Advisers now owns 141,790 shares of the medical instruments supplier’s stock valued at $21,260,000 after buying an additional 403 shares during the last quarter. IFP Advisors Inc acquired a new stake in Glaukos during the 4th quarter valued at approximately $43,000. US Bancorp DE raised its holdings in Glaukos by 8.3% during the 4th quarter. US Bancorp DE now owns 6,099 shares of the medical instruments supplier’s stock worth $914,000 after purchasing an additional 470 shares during the last quarter. CIBC Asset Management Inc bought a new position in Glaukos during the 4th quarter worth approximately $227,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Glaukos in the 4th quarter worth approximately $16,910,000. 99.04% of the stock is owned by institutional investors.

Insider Activity

In related news, CFO Alex R. Thurman sold 1,520 shares of the business’s stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the sale, the chief financial officer now owns 53,431 shares of the company’s stock, valued at $5,708,568.04. The trade was a 2.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 5.80% of the stock is currently owned by insiders.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.